CAPLIPOINT Stock Overview
Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Caplin Point Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,456.20 |
| 52 Week High | ₹1,619.05 |
| 52 Week Low | ₹785.00 |
| Beta | 0.42 |
| 11 Month Change | 13.05% |
| 3 Month Change | 13.69% |
| 1 Year Change | 85.21% |
| 33 Year Change | 120.82% |
| 5 Year Change | 252.98% |
| Change since IPO | 3,967.60% |
Recent News & Updates
Recent updates
Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues
May 24
Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?
May 04Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement
Mar 07With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 24Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise
Sep 15Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50
Aug 11We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise
Sep 23Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year
Sep 11Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?
Jul 22Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00
May 15A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Jan 21Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?
Oct 20Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50
Sep 17Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50
Sep 03Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price
Aug 27Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?
Jun 12Estimating The Fair Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Apr 29Does Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Have A Place In Your Dividend Portfolio?
Mar 24We Think Caplin Point Laboratories (NSE:CAPLIPOINT) Can Stay On Top Of Its Debt
Mar 11Do Caplin Point Laboratories's (NSE:CAPLIPOINT) Earnings Warrant Your Attention?
Feb 26What We Learned About Caplin Point Laboratories' (NSE:CAPLIPOINT) CEO Pay
Feb 14Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Feb 02Can You Imagine How Jubilant Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Feel About Its 105% Share Price Gain?
Jan 21
Does This Valuation Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Imply Investors Are Overpaying?
Jan 09Could The Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Ownership Structure Tell Us Something Useful?
Dec 28Is It Worth Buying Caplin Point Laboratories Limited (NSE:CAPLIPOINT) For Its 0.5% Dividend Yield?
Dec 16We Think Caplin Point Laboratories (NSE:CAPLIPOINT) Can Stay On Top Of Its Debt
Dec 04Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?
Nov 21Here's What We Learned About The CEO Pay At Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Nov 08Shareholder Returns
| CAPLIPOINT | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.1% | 3.7% | 2.0% |
| 1Y | 85.2% | 50.5% | 44.4% |
Return vs Industry: CAPLIPOINT exceeded the Indian Pharmaceuticals industry which returned 50.5% over the past year.
Return vs Market: CAPLIPOINT exceeded the Indian Market which returned 44.4% over the past year.
Price Volatility
| CAPLIPOINT volatility | |
|---|---|
| CAPLIPOINT Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: CAPLIPOINT has not had significant price volatility in the past 3 months.
Volatility Over Time: CAPLIPOINT's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 1,642 | Sridhar Ganesan | www.caplinpoint.net |
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. It provides liquid and lyophilized vials, pre-filled syringes, 3-pc ophthalmic droppers, pre-mix bags, dry and liquid syrups-bottles, tables, soft gels, capsules, suppositories, liquid and emulsion injectables in ampoules and vials, topicals, and sachets. The company was incorporated in 1990 and is headquartered in Chennai, India.
Caplin Point Laboratories Limited Fundamentals Summary
| CAPLIPOINT fundamental statistics | |
|---|---|
| Market cap | ₹110.93b |
| Earnings (TTM) | ₹4.57b |
| Revenue (TTM) | ₹16.94b |
24.3x
P/E Ratio6.5x
P/S RatioIs CAPLIPOINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAPLIPOINT income statement (TTM) | |
|---|---|
| Revenue | ₹16.94b |
| Cost of Revenue | ₹7.24b |
| Gross Profit | ₹9.70b |
| Other Expenses | ₹5.13b |
| Earnings | ₹4.57b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 60.13 |
| Gross Margin | 57.25% |
| Net Profit Margin | 26.98% |
| Debt/Equity Ratio | 0.01% |
How did CAPLIPOINT perform over the long term?
See historical performance and comparison